Raymond James lowered the firm’s price target on Zimmer Biomet (ZBH) to $104 from $119 and keeps an Outperform rating on the shares. Zimmer Biomet’s Q1 results were slightly better than expected, but the limited clarity around the potential tariff impact in 2026, along with some timing shifts creating an even steeper 2H25 ramp, is weighing on sentiment, the analyst tells investors in a research note. The firm still sees some underlying growth drivers.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $115 from $130 at Baird
- Cautious Hold on Zimmer Biomet Amid Mixed Performance and Strategic Adjustments
- Zimmer Biomet price target lowered to $110 from $135 at BofA
- Zimmer Biomet price target lowered to $115 from $138 at Stifel
- Cautious Outlook for Zimmer Biomet Holdings Amid Tariff Exposure and Conservative Guidance